4-fluoro-N-(6-hydroxyhexyl)benzamide | 1402413-58-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-fluoro-N-(6-hydroxyhexyl)benzamide
• 英文别名: 4-fluoro-N-(6-hydroxyhexyl)-benzamide
• CAS: 1402413-58-4
• 化学式: C₁₃H₁₈FNO₂
• 分子量: 239.29
• InChiKey: IDQLHXWLURHYQH-UHFFFAOYSA-N

物化性质

• 沸点：
  410.4±30.0 °C(Predicted)
• 密度：
  1.118±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-fluoro-N-(6-hydroxyhexyl)benzamide 、 2,3,4,6-四乙酰氧基-alpha-D-吡喃糖溴化物 在 silver carbonate 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 生成 1-O-(6-p-fluorobenzoylamino-1-hexyl)-2,3,4,6-tetra-O-acetyl-β-galactopyranoside
  参考文献：
  名称：

  18F-Labeled Monomeric Galactose Derivative Used as Tomography Probe

  摘要：

  提供了标记为A18F的单体半乳糖衍生物作为一种断层扫描探针。该衍生物是一种正电子发射断层扫描（PET）探针。该衍生物在动物体内具有高亲和力和良好稳定性。该衍生物可以作为一种替代葡萄糖代谢成像剂用于临床检查和定量。

  公开号：

  US20120259102A1
• 作为产物：
  描述：

  6-氨基-1-己醇 、 对氟苯甲酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 以90%的产率得到4-fluoro-N-(6-hydroxyhexyl)benzamide
  参考文献：
  名称：

  18F-Labeled Monomeric Galactose Derivative Used as Tomography Probe

  摘要：

  提供了标记为A18F的单体半乳糖衍生物作为一种断层扫描探针。该衍生物是一种正电子发射断层扫描（PET）探针。该衍生物在动物体内具有高亲和力和良好稳定性。该衍生物可以作为一种替代葡萄糖代谢成像剂用于临床检查和定量。

  公开号：

  US20120259102A1

文献信息

• 18F-labeled monomeric galactose derivative used as tomography probe
  申请人：Duh Ting-Shien

  公开号：US08961931B2

  公开（公告）日：2015-02-24

  A 18F-labeled monomeric galactose derivative is provided as a tomography probe. The derivative is a positron emission tomography (PET) probe. The derivative has high affinity and good stability in animal's body. The derivative can be an alternative glucose metabolism imaging agent used in clinic examination and quantification.

  提供了一种标记为18F的单体半乳糖衍生物，作为断层扫描探针。该衍生物是正电子发射断层扫描（PET）探针。该衍生物在动物体内具有高亲和力和良好的稳定性。该衍生物可以成为替代葡萄糖代谢成像剂在临床检查和定量中使用的选择。
• MIRROR AND REFLECTIVE DEVICE FOR GENERATING SOLAR POWER
  申请人：Konica Minolta, Inc.

  公开号：EP2693240A1

  公开（公告）日：2014-02-05

  A hard coat layer 8 is provided on an outermost surface layer of a film mirror 10 having a first resin base material 1 and a silver reflection layer 3, and the hard coat layer 8 contains a polyfunctional acrylic monomer and a silicon resin having an active energy ray reactive unsaturated group.

  在具有第一树脂基材 1 和银反射层 3 的薄膜镜面 10 的最外表面层上设有硬涂层 8，硬涂层 8 包含多官能丙烯酸单体和具有活性能量射线反应不饱和基团的硅树脂。
• US8961931B2
  申请人：——

  公开号：US8961931B2

  公开（公告）日：2015-02-24
• US9057867B2
  申请人：——

  公开号：US9057867B2

  公开（公告）日：2015-06-16
• 18F-FBHGal for asialoglycoprotein receptor imaging in a hepatic fibrosis mouse model
  作者：Hao-Wen Kao、Chuan-Lin Chen、Wen-Yi Chang、Jenn-Tzong Chen、Wuu-Jyh Lin、Ren-Shyan Liu、Hsin-Ell Wang

  DOI：10.1016/j.bmc.2012.12.022

  日期：2013.2

  Quantification of the expression of asialoglycoprotein receptor (ASGPR), which is located on the hepatocyte membrane with high-affinity for galactose residues, can help assess ASGPR-related liver diseases. A hepatic fibrosis mouse model with lower asialoglycoprotein receptor expression was established by dimethylnitrosamine (DMN) administration. This study developed and demonstrated that 4-F-18-fluoro-N-(6-((3,4,5-trihydroxy-6-(hydroxymethyl)tetra hydro-2 H-pyran-2-y1)oxy)hexyl)ben zam ide (F-18-FBHGal), a new F-18-labeled monovalent galactose derivative, is an asialoglycoprotein receptor (ASGPR)-specific PET probe in a normal and a hepatic fibrosis mouse models. Immunoassay exhibited a linear correlation between the accumulation of GaIH-FITC, a fluorescent surrogate of FBHGal, and the amount of ASGPR. A significant reduction in HepG2 cellular uptake (P <0.0001) was observed using confocal microscopy when co-incubated with 0.5 mu M of asialofetuin, a well known ASGPR blocking agent. Animal studies showed the accumulation of F-18-FBHGal in fibrosis liver (14.84 +/- 1.10 %ID/g) was appreciably decreased compared with that in normal liver (20.50 +/- 1.51 %ID/g, P <0.01) at 30 min post-injection. The receptor indexes (liver/liver-plus-heart ratio at 30 min post-injection) of hepatic fibrosis mice derived from both microPET imaging and biodistribution study were significantly lower (P <0.01) than those of normal mice. The pharmacokinetic parameters (7(1/2)alpha, T-1/2 beta, AUC and Cl) derived from microPET images revealed prolonged systemic circulation of F-18-FBHGal in hepatic fibrosis mice compared to that in normal mice. The findings in biological characterizations suggest that 18F-FBHGal is a feasible agent for PET imaging of hepatic fibrosis in mice and may provide new insights into ASGPR-related liver dysfunction. (C) 2012 Elsevier Ltd. All rights reserved.